Introduction {#sec1}
============

*Lodderomyces elongisporus* was considered as a sexual state of *Candida parapsilosis* [@bib1], and its role in human infection was unknown until recently. Sequencing of the ribosomal RNA gene revealed that *L. elongisporus* represents a distinct species [@bib2]. The aetiologic role of *L. elongisporus* was subsequently established in human infections [@bib3]. Of ten clinical isolates identified as *L. elongisporus,* eight originated from Mexico, while one each came from China and Malaysia [@bib4]. These isolates were previously misidentified as *C*. *parapsilosis* by the VITEK 2 yeast identification system. *L. elongisporus* has been isolated from bloodstream and from the catheter tip of a case of suspected fungaemia patient in Kuwait [@bib3], [@bib4], [@bib5].

Here we describe a case of primary fungaemia by *L. elongisporus* that progressed rapidly with fatal outcome despite prompt initiation of treatment with caspofungin.

Case summary {#sec2}
============

A 71-year-old woman with a history of hypertension, ischaemic heart disease and peripheral vascular disease was brought to emergency room in an unconscious state. Head computed tomographic scan revealed a stroke. On day 2, her condition deteriorated rapidly, requiring inotropic support. She developed septic shock, as indicated by elevated levels of inflammatory markers (erythrocyte sedimentation rate, 70 mm/h; C-reactive protein, 78 mg/L). Blood obtained at this time grew a yeast in both aerobic and anaerobic BacT/ALERT culture bottles. Pending identification, caspofungin was administered immediately, but she died on day 3 of her hospital stay.

The yeast isolate (Kw553/18) was identified as *C. parapsilosis* by the VITEK 2 yeast identification system (bioMérieux, Marcy l'Etoile, France). The isolate was referred to the Mycology Reference Laboratory for further characterization. On CHROMagar Candida (CHROMagar, Paris, France), it produced turquoise blue colonies ([Fig. 1](#fig1){ref-type="fig"}) instead of cream-coloured colonies with a pinkish shade, which is characteristic of *C*. *parapsilosis,* thus prompting further identification. On acetate ascospore agar after 7 days of incubation at 25°C, the isolate formed long ellipsoidal-shaped ascospores ([Fig. 2](#fig2){ref-type="fig"}), suggesting its identity as *L. elongisporus*. The internally transcribed spacer region of ribosomal DNA was amplified and sequenced as described previously [@bib6], [@bib7]. DNA sequence data comparisons of Kw553/18 (European Molecular Biology Laboratory accession no. LS482924) showed complete (100%) identity with the corresponding sequence from *L. elongisporus* type strain (ATCC 11503) but only 83% identity with the sequence from reference *C*. *parapsilosis* strain (ATCC 22019) [@bib8]. The findings also suggested that *Candida* species isolates forming turquoise blue colonies on CHROMagar Candida and producing ascospores on acetate ascospore agar can be presumptively identified as *L. elongisporus* for laboratories where molecular identification methods are not available.Fig. 1Colony characteristics of *Lodderomyces elongisporus* (Kw553/18) (A), *Candida metappsilosis* (B), *C*. *orthopsilosis* (C) and *C*. *parapsilosis* (D) on CHROMagar Candida. Note turquoise blue colonies of *L. elongisporus*.Fig. 1Fig. 2Ellipsoidal to elongate ascospores (green) of *Lodderomyces elongisporus* produced on acetate ascospore agar and stained with Schaeffer-Fulton stain. Original magnification, ×1000.Fig. 2

Antifungal susceptibility was determined by Etest (bioMérieux) on RPMI 1640 medium supplemented with 2% glucose, as described previously [@bib9]. MIC values (μg/mL) were as follows: amphotericin B, 0.012; fluconazole, 0.125; voriconazole, 0.004; posaconazole, 0.003; itraconazole, 0.008; flucytosine, 0.064; caspofungin, 0.064; micafungin, 0.003.

Results {#sec3}
=======

The unusual aspect of our case is that there were no apparent risk factors in the patient when fungaemia was diagnosed. However, she had a history of heart disease and had also experienced a stroke. She was not receiving any antibiotics; nor had any central lines been emplaced. She was hospitalized earlier for lower limb ischaemia due to peripheral vascular disease, but she was discharged 2 weeks before the current episode. It is not clear how she developed fungaemia as a result of this unusual yeast in the absence of any known risk factors. However, the possibility of inoculation of the yeast from the skin or translocation from the gastrointestinal tract cannot be ruled out.

Although *L. elongisporus* is a recognized bloodstream pathogen [@bib3], little is known about its virulence attributes or its environmental niche. Like other opportunistic yeast pathogens, this species is also capable of causing diverse clinical conditions, including endocarditis. The species has a global prevalence: it has been isolated from patients in distant geographic regions, including Mexico, Malaysia and China [@bib3], Australia [@bib10], the Middle East [@bib5], [@bib11], Japan [@bib12], Spain [@bib13] and Korea [@bib14] ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}).Table 1Summary of salient findings of published cases of *Lodderomyces elongisporus* fungaemiaTable 1Case no.StudyCountryAge/sexComorbidities or risk factorsIdentification method1Daveson 2012 [@bib10]Australia30/MEndocarditis, osteomyelitis and brain embolic lesions; intravenous drug user•Blue-green colonies on CHROMagar (BD Diagnostics).•ITS region sequence analysis.2[a](#tbl1fna){ref-type="table-fn"}Ahmad 2013 [@bib5]Kuwait63/MCardiovascular attack, vascular catheter•Turquoise blue colonies on CHROMagar Candida (Becton Dickinson).•Identified as *Candida parapsilosis* by VITEK 2 yeast identification system (bioMérieux).•PCR sequencing of ITS region of rDNA.3Taj-Aldeen 2014 [@bib11]Qatar22/MTrauma•MALDI-TOF MS.•Sequence analysis of ITS region and D1--D2 domains of rDNA.4Hatanaka 2016 [@bib12]Japan39/MThoracoabdominal aortic replacement complicated with aortoesophageal fistula, catheter•Dark green colonies *Candida* agar medium.•Identified as *C. parapsilosis* by VITEK 2 system (bioMérieux).•Sequence analysis of ITS region and D1--D2 domains of rDNA.5Fernández-Ruiz 2017 [@bib13]Spain79/MCOPD, diabetes mellitus, ESRD•Sequencing ITS region of rDNA.6Lee 2018 [@bib14]Korea56/FLung cancer, receiving immunosuppressive agents, vascular catheter•Turquoise blue colony on CHROMagar.•*Candida* medium.•VITEK 2 YST ID (bioMérieux) and API 20C AUX (bioMérieux) system identified it as *C. parapsilosis*.•MALDI-TOF MS (Bruker Daltonics) analysis indicated likely identification of *L. elongisporus* (score value = 1.79).•Sequence analysis of ITS region of rDNA.7Present caseKuwait71/FHypertension, ischaemic heart disease, peripheral vascular disease•Blue colonies in CHROMagar Candida.•Identified as *C. parapsilosis* in VITEK 2 yeast identification system (bioMérieux).•PCR sequencing of ITS region of rDNA.[^1][^2]Table 2Treatment and outcome of *Lodderomyces elongisporus* fungaemiaTable 2Case no.StudyTreatmentOutcome1Daveson 2012 [@bib10]Caspofungin before cardiac surgery, then amphotericin B plus flucytosine followed by voriconazoleSurvived2[a](#tbl2fna){ref-type="table-fn"}Ahmad 2013 [@bib5]FluconazoleSurvived3Taj-Aldeen 2014 [@bib11]Caspofungin, fluconazoleDied4Hatanaka 2016 [@bib12]MicafunginSurvived5Fernández-Ruiz 2017 [@bib13]Caspofungin 3 daysDied6Lee 2018 [@bib14]Not providedDied before removal of indwelling catheter or antifungal treatment7Present caseCaspofungin (one dose)Died[^3]

The salient findings of seven individual case reports of *L. elongisporus* fungaemia are summarized in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}. All patients had associated comorbidities and/or risk factors including an intravenous drug user (patient 1). Four (57.5%) of seven patients died even though six patients were treated with antifungal drugs. Because the number of patients is small, it is difficult to assess the impact of antifungal therapy on the outcome. It is also not clear if use of echinocandins (caspofungin in four patients and micafungin in one patient) was an appropriate therapy for *L. elongisporus* fungaemia because three of five patients died.

Discussion {#sec4}
==========

Data on antifungal susceptibility of *L. elongisporus* are scanty, and no susceptibility breakpoints are available. *C*. *parapsilosis* complex members, to which *L. elongisporus* is closely related, generally show reduced susceptibility to echinocandins [@bib15]. The *in vitro* MIC values for antifungal drugs for *L. elongisporus* isolates were within the susceptible range ([Table 3](#tbl3){ref-type="table"}) [@bib3], [@bib5], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib16]. Although echinocandins have lower *in vitro* activity against *C*. *parapsilosis* complex members to which *L. elongisporus* is closely related, the current Infectious Disease Society of America guidelines still favour therapeutic use of echinocandins for the treatment of candidaemia caused by *C*. *parapsilosis* [@bib17].Table 3Antifungal susceptibility profile of *Lodderomyces elongisporus* isolatesTable 3StudyNo. of isolateMethodMIC (μg/mL) of:AP5-FCFLITKEVOPOSISACSANDMYCLockhart 2008 [@bib3]9BMD, CLSI0.37--0.75NA0.12--0.025NANANANANA0.015--0.030.015--0.120.015--0.03Tay 2009 [@bib16]1Etest0.012NA0.1250.0470.0030.004NANANANANADaveson 2012 [@bib10]1NA0.250.06≤0.1250.06≤0.008≤0.0080.03NA0.03NANAAhmad 2013 [@bib5]1EtestNA0.0940.32NANA0.0020.023NA0.094NANATaj-Aldeen 2014 [@bib11]1BMD, CLSI0.5NA0.250.031NA*\<*0.0160.063*\<*0.0160.50.016NAHatanaka 2016 [@bib12]1BMD, CLSI0.250.50.50.25NA0.015NANANANA0.015Fernández-Ruiz 2017 [@bib13]1BMD, CLSI0.0310.125NANA0.00170.007NANA0.0150.015Lee 2018 [@bib14]1ATB Fungus 30.251.001.00NANA0.12NANA0.25NA0.06Present case1Etest0.0120.0640.1250.0080.0030.0040.003NA0.0640.0080.032[^4]

Uncommon yeast pathogens are often misidentified as a result of limitations of the currently available commercial yeast identification systems, such as VITEK 2, which identify *C*. *parapsilosis* complex but do not distinguish *C. parapsilosis, C. orthopsilosis, C. metapsilosis* and *L. elongisporus* [@bib18]. A retrospective characterization of 380 *C. parapsilosis* complex isolates available in the Mycology Reference Laboratory culture collection and previously speciated by VITEK 2 by a multiplex PCR assay [@bib19] that simultaneously detected *C. parapsilosis, C. orthopsilosis, C. metapsilosis* and *L. elongisporus* identified three *L. elongisporus* isolates. One isolate was obtained from sputum of a cancer patient (isolate Kw2486/06); another isolate (Kw554/08) was recovered from the catheter tip of a patient with fungaemia [@bib5]; and a third isolate (Kw3047/14) was isolated from the bloodstream of a cancer patient. However, clinical details of the two cancer patients were not available. Recently matrix-assisted laser desorption/ionization time-of-flight mass spectrometry has also been used for the identification of *L. elongisporus* [@bib20].

Rare yeast species often exhibit reduced susceptibility to one or more commonly used antifungal agents [@bib18]. A number of factors have been attributed to their increased occurrence, such as prolonged survival of seriously ill patients admitted in intensive care units, administration of multiple broad-spectrum antibiotics, dependence on life support systems and extended use of intravascular catheters [@bib21]. It is also possible that these relatively less susceptible yeasts take advantage of the selection pressure created by prophylactic and therapeutic use of antifungal agents, resulting in increased colonization and invasive infection [@bib18], [@bib21]. Perhaps a delay in accurate identification and a lack of experience in the management of such rare yeast infections pose diagnostic and therapeutic challenges with consequently higher mortality rates.
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[^1]: COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; ITS, internally transcribed spacer; MALDI-TOF MS, matrix-assisted desorption ionization--time of flight mass spectrometry; rDNA, recombinant DNA.

[^2]: In case 2, *L. elongisporus* was isolated from catheter tip culture.

[^3]: In case 2, L elongisporus was isolated from catheter tip culture.

[^4]: 5-FC, 5-flurocytosin; AND, anidulafungin; AP, amphotericin; BMD, broth microdilution; CLSI, Clinical and Laboratory Standards Institute; CS, caspofungin; FL, fluconazole; ISA, isavuconazole; IT, itraconazole; KE, ketoconazole; MYC, micafungin; NA, not available; POS, posaconazole; VO, voriconazole.
